60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements
WASHINGTON, Jan. 16, 2024 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that on January 10, 2024 it received written notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) stating the Company has regained compliance with the minimum bid price requirement (the “Minimum Bid Price Requirement”), as set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.
Related news for (SXTPW)
- 60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer
- 60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering
- 60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering
- 60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting